Fig 6. Effect of mutations on neutralization by antibodies elicited by 2x BNT162b2 vaccination, Delta breakthrough after 2x mRNA vaccination, or primary Delta infection.

(A) Neutralization titer 50% (NT50) of spike-pseudotyped lentiviral particles by sera or plasmas from individuals with various exposure histories. The leftmost spike is D614G, which was circulating in 2020. The point mutations and depletion of RBD-binding antibodies are in the indicated spike background (D614G or Delta). Bars represent geometric mean. Dashed line indicates assay limit of detection. (B) Fold-decrease in neutralization by sera or plasmas from individuals with various exposure histories against K417N (left) or E484K (right) in the Delta and D614G spikes, compared to the homologous spike (dashed line at 1). Points represent the geometric mean across cohorts (NT50s plotted in (A)). Error bars represent geometric standard deviation. The neutralization assays with 2x BNT162b2, Delta breakthrough, and Delta primary infection were newly performed in this study, and assays with 2x mRNA-1273 and early 2020 plasmas were performed in (12,29) and are reanalyzed here. Full neutralization curves are in S7 Fig and numerical NT50s are in S1 Data and online at https://github.com/jbloomlab/SARS-CoV-2-RBD_Delta/blob/main/experimental_data/results/neut_titers/combined_neut_titers.csv.